Zacks Research Predicts Sanofi's Earnings for Q2 (NASDAQ:SNY)

February 23, 2025 11:29 PM PST | By Team Kalkine Media

Zacks Research Predicts Sanofi's Earnings for Q2 (NASDAQ:SNY) — Image source: Shutterstock

Market Performance and Institutional Investments

As of a recent Monday, Sanofi's shares opened at $54.46. Over the past year, the stock has fluctuated between a low of $45.22 and a high of $58.97. Sanofi's financial health is highlighted by a debt-to-equity ratio of 0.15 and a current ratio of 1.46. The company's market capitalization stands at approximately $138.21 billion.

Institutional investors have actively participated in Sanofi's market, reflecting varied engagement levels. Price T Rowe Associates Inc. significantly increased its holdings by 88.5% during the fourth quarter, accumulating 10,843,682 shares. Similarly, Boston Partners and Magnetar Financial LLC expanded their stakes by substantial percentages, showcasing confidence in the company's future prospects. Approximately 14.04% of Sanofi’s stock is owned by hedge funds and other institutional investors.

Sanofi operates as a prominent healthcare company, involved in the research, development, manufacturing, and marketing of therapeutic solutions on a global scale. The company's operations span across Pharmaceuticals, Vaccines, and Consumer Healthcare segments. Sanofi offers a diverse range of products, including specialty care for conditions such as neurology and immunology, rare diseases, and oncology, along with medical solutions for diabetes and cardiovascular ailments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.